Question to the Department of Health and Social Care:

To ask His Majesty's Government what assessment they have made of the impact of the mechanisms for pricing schemes for innovative medicines in the UK, and those in comparative countries such as (1) Germany, (2) Spain, and (3) Ireland.

No assessment has been made.

The Government is open to ideas about how a successor to Voluntary Scheme for Branded Medicines Pricing and Access should operate from 2024 onwards and will work with industry and apply learning from approaches in the United Kingdom and internationally to agree a mutually beneficial successor that that supports better patient outcomes; ensures the sustainability of National Health Service spend on branded medicines; and enables a strong UK life sciences industry.